Neeraj Bajaj, MD
Interventional Cardiology · Orlando, FLNPI 1407017957
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,074 of the $7,306 with a category attached, or 69.5%. 28 manufacturers reported payments, led by Penumbra, Inc. at 43.0% of the total. Reporting peaked in 2024 at $2,418 and has fallen 58.2% since, to $1,011 in 2025. That places this record below the midpoint for interventional cardiology clinicians in FL, where the typical reported total is $7,973.
Across 140 payments — averaging $52.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Penumbra, Inc.$3K
- Abiomed$1K
- Medtronic$576
- Inari Medical, Inc.$331
- Boston Scientific$303
- Abbott$271
- plus $1K from 22 others
What the payments were for
- Travel & lodging$1,97427%
- Food & beverage$5,07469%
- Gifts$2574%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Penumbra, Inc. | 9 | $3,139 |
| Abiomed | 22 | $1,298 |
| Medtronic | 40 | $576 |
| Inari Medical, Inc. | 3 | $331 |
| Boston Scientific | 9 | $303 |
| Abbott | 5 | $271 |
| Shockwave Medical, Inc | 2 | $240 |
| E.r. Squibb & Sons, L.L.C. | 9 | $234 |
| Johnson & Johnson | 1 | $125 |
| Novartis | 4 | $85 |
| Pfizer | 5 | $80 |
| Cardiovascular Systems Inc. | 4 | $65 |
| Teleflex LLC | 2 | $55 |
| Boehringer Ingelheim | 3 | $54 |
| Cordis US CORP. | 2 | $52 |
| AstraZeneca | 3 | $50 |
| Cleerly, Inc. | 1 | $48 |
| Novo Nordisk | 3 | $47 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $39 |
| Actelion Pharmaceuticals US, Inc. | 1 | $36 |
| Amgen | 2 | $32 |
| Heartflow, Inc. | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $17 |
| Livanova USA, Inc. | 1 | $15 |
| Bardy Diagnostics, Inc. | 1 | $13 |
| Tactile Systems Technology Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Indigo System$2,383
- Indigo$743
- Impella$425
- FLOWTRIEVER CATHETER, S$330
- CT THROMBECTOMY SYSTEM KIT$330
- Vascular Lithotripsy$240
- AMPLATZER Occluders$184
- GENERAL VASCULAR INTERVENTION$139
- XARELTO$125
- SYMPLICITY G3$120
- CAMZYOS$115
How this compares
$7,306 in reported general payments places this provider in the 45th percentile of 623 interventional cardiology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 212 | $253,274 |
| EntrestoSacubitril/Valsartan | 46 | $74,853 |
| JardianceEmpagliflozin | 46 | $65,372 |
| Repatha SureclickEvolocumab | 57 | $58,928 |
| BrilintaTicagrelor | 47 | $40,745 |
| XareltoRivaroxaban | 24 | $37,254 |
| VascepaIcosapent Ethyl | 24 | $16,248 |
| Ezetimibe | 310 | $5,896 |
| Atorvastatin Calcium | 441 | $4,569 |
| Rosuvastatin Calcium | 219 | $3,345 |
| Metoprolol Succinate | 211 | $2,162 |
| ClopidogrelClopidogrel Bisulfate | 156 | $1,449 |
| Amiodarone Hcl | 19 | $1,439 |
| Losartan Potassium | 134 | $1,122 |
| Icosapent Ethyl | 12 | $1,004 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $80 | $253,274212 claims |
| NovartisEntresto | $85 | $74,85346 claims |
| Boehringer IngelheimJardiance | $54 | $65,37246 claims |
| AstraZenecaBrilinta | $50 | $40,74547 claims |
| Johnson & JohnsonXarelto | $125 | $37,25424 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 623 interventional cardiology providers in Florida.
Other interventional cardiology in Orlando
- Zahid AminOrlando$635K
- Bruce SteinOrlando$151K
- Aalok PatelOrlando$115K
- Vijaykumar KasiOrlando$77K
- Farhan KhawajaOrlando$77K
- Arthur LeeGainesville$1.8M
- Santhosh MathewsBradenton$1.4M
- Siddharth WayangankarJacksonville$1.2M
- Patrick CambierTrinity$901K
- Rohit AminPensacola$560K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.